USPTO serial 76373789
IPSOGEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 7, 2005
- Examiner
- CASE, LEIGH CAROLINE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.
Need help with IPSOGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
MARSIGLIA, FR
MARSEILLE, FR
HILDEN, DE
F-13273 Marseille Cedex 09, FR
F-13273 Marseille Cedex 09, FR
F-13273 Marseille Cedex 09, FR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Daniel M. Gurfinkel
Daniel M. Gurfinkel Dennemeyer & Associates, LLC230 W. Monroe St.Suite 2100Chicago, IL 60606Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biological reagents for diagnoses and for identification of biological systems [ ; pharmaceutical products, namely, preparations, chemical preparations and chemico-pharmaceutical preparations for treating illnesses, namely, genetic and infectious illnesses namely, acute leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, AML, acute monocytic leukemia, AML, acute promyelocytic leukemia, APL, adenocarcinoma, adenocarcinoma lung cancer, adenocystic carcinoma, adenoid cystic breast cancer, adenoid cystic arcinoma, adrenal gland cancer, advanced breast cancer, aggressive breast cancer, ameloblastoma, anal, anus cancer; angiosarcoma, appendix cancer, appendiceal cancer, astrocytoma, arrett's esophagus, bartholin gland cancer, basal cell carcinoma, basal cell skin cancer, B-cell lymphoma, bilateral breast cancer, bile duct cancer, bladder cancer, bladder metastases, bone cancer, bone marrow transplantation, Bowen's disease, bone metastases, borderline ovarian cancer, brain metastases, brain tumor, brainstem glioma, breast cancer, breast reconstruction, bronchial cancer, bronchioalveolar lung cancer, buttock cancer, cancer of unknown primary site, CUPS, cancer prevention, carcinoma of unknown primary, carcinoid, carcinoid syndrome, carcinoid tumor, carcinosarcoma, cavernous sinus cancer, cecum cancer, central nervous system lymphoma, centrocytic lymphoma, cerebral astrocytoma, cervix cancer, cervical cancer, chest tumors, mediastinum tumors, chiasmal glioma, childhood cancers, chondroma, intracranial, chordoma, chondrosarcoma, chorioadenoma destruens, choroids plexus carcinoma, choroidal melanoma, chronic leukemia, chronic lymphocytic leukemia, CLL, chronic myelogenous leukemia, CML, clear cell ovarian cancer, clear cell sarcoma, CNS lymphoma, colon cancer, adenocarcinoma of the colon, adenomatous polyps, polyps, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, DCIS - ductal carcinoma in situ, dermatofibrosarcoma protuberans, desmoidtumor, desmoplastic tumor, diffuse lymphoma, diffuse, large-cell lymphoma, ductal carcinoma in situ, DCIS, duodenalcancer dysgerminoma, early stage prostate cancer, endocrine cancer, endometrial cancer, endometrial stromal sarcoma, ependymoma, esophagus cancer, esophageal cancer, esophagus cancer of the gastroesophageal junction, esthesioneuroblastoma, Ewing's sarcoma, extensive stage small cell lung cancer, extrahepatic bile duct cancer, extraskeletal chondrosarcoma, extraskeletal Ewing's sarcoma, extraskeletal osteosarcoma, eye metastases, eye cancer, fallopian tube cancer, fibrosarcoma, fibrous histiocytoma, follicular lymphoma, follicular, small-cleaved cell lymphoma, gallbladder cancer, gastric cancer, gastrinoma, gastro-esophageal, GE junction, cancer, gastrointestinal lymphoma, GE junction esophageal cancer, germ cell tumor, gestational trophoblastic disease, giant cell bone tumor, glioblastoma, glioma, gliomatosis, granular lymphocytic lymphoma, granulocytic leukemia, granulosa cell ovarian cancer, hairy cell leukemia, head and neck cancer, hemangioendothelioma, hemangiopericytoma, hepatocelluar carcinoma, high-grade lymphoma, high-risk breast cancer, histiocytoma, malignant, Hodgkin's disease, Hodgkin's disease in pregnancy, hormone-refractory prostate cancer, in situ breast cancer, insulinoma, intermediate-grade lymphoma, intraocular melanoma, invasive lobular breast cancer, islet cell pancreatic cancer, Kaposi's sarcoma, kidney cancer, krukenberg tumor, large-cell lung cancer, large-cell lymphoma, large-cell, diffuse lymphoma, larynx cancer, laryngeal cancer, leiomyosarcoma, lentigo maligna, leukemia, linitis plastica, limited stage small cell lung cancer, lip cancer, liposarcoma, liver cancer, recurrent liver cancer, undifferentiated liver cancer, lobular carcinoma in situ, LCIS, lobular hyperplasia low-grade lymphoma, lung cancer, non-small cell lung cancer, epidermoid carcinoma, large cell carcinoma, squamous cell carcinoma, spindal cell variant, pancoast tumors, superior sSulcus tumors, undifferentiated carcinoma, lung metastases, lymph node excision, lymphangitic metastasis, lymph node metastases, lymphoblastic leukemia, lymphoblastic lymphoma, lymphocytic lymphoma, lymphoma, non-Hodgkin's lymphoma, malignant ascites, malignant hemangiopericytoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant pleural effusion, malignant schwannoma, MALT lymphoma, mantle cell lymphoma, medlastinal tumor, medulloblastoma, melanoma, meningeal cancer, meningeal metastases, meningioma, merkel cell carcinoma, merkel cell skin cancer, mesothelioma, mesenchymal chondrosarcoma, metastatic melanoma, mixed mullerian tumor, mucinous carcinoma, multiple myeloma, muscle-invasive bladder tumor, mycosis fungoides, myelodysplasia, myelodysplastic syndrome, myeloma, Bence-Jones, myeloproliferative disorder, nail/nail bed cancer, nasal cavity cancer, nasopharynx cancer, neck, radical dissection, neoplastic meningitis, nerve sheath tumors, neuroblastoma, neuroendocrine tumor, adenosquamous carcinoma, adenocarcinoma, ocular melanoma, olfactory cancer, oligodendroglioma, optic glioma, oral cancer, orbital lumphoma, orophaiynx cancer, osteogenic sarcoma, osteosarcoma, ovarian cancer, Pagets disease of the breast, pancreatic cancer, recurrent pancreatic cancer, borderline pancreatic tumors, mucinous cystic tumor with dysplasia, intraductal papillary mucinous tumor with dysplasia, pseudopapillary solid tumor, islet cell tumors, gastrinoma, paraganglioma, paranasal sinus cancer, paraneoplastic syndromes, parathyroid cancer, parotid gland cancer, pelvic tumor, penis cancer, periampullary cancer, pericardial effusion, peripheral nerve sheath tumor, peripheral T-cell lymphoma, peritoneal cancer, extraovarian serous carcinoma, extraovarian peritoneal serious papillary carcinoma, serous surface carcinoma of the peritoneum, serous surface papillary carcinoma, papillary serous carcinoma of the peritoneum, multiple focal peritoneal papillary carcinoma, primary peritoneal papillary serous adenocarcinoma, peritoneal carcinomatosis, pheochromocytoma, pinealoma, pineoblastoma, plasmacytoma, pleura cancer, pleura metastases, preleukemia, primary central nervous system lymphoma, primitive neuroctodermal tumor, PNET, plolymphocytic leukemia, promyelocytic leukemia, prophylactic mastectomy, prostate cancer, prostatic intraepithelial neoplasia, PIN, PSA, pseudomyxoma peritonei, rectal cancer, recurrent colon cancer, recurrent colorectal cancer, recurrent lung cancer, recurrent melanoma, recurrent ovarian cancer, recurrent prostate cancer, recurrent rectal cancer, relapsed lymphoma, renal cell carcinoma, renal pelvis cancer, retinoblastoma, rhabdomyosarcoma, Richters syndrome, rising PSA as an indication of recurrent prostate cancer, salivary gland cancer, sarcoma of bone, sarcomatoid carcinoma; sebaceous carcinoma, sezary syndrome, sinus, cavernous, sinus cancer, skin cancer, skin metastases, small cell bladder cancer, small cell lung cancer, small cleaved cell lymphoma, small intestine cancer, soft tissue lymphoma, soft tissue sarcoma, synovial sarcoma, spinal cord cancer, spindle cell thyroid cancer, squamous cell cancer, non-skin, squamous cell lung cancer, squamous cell skin cancer, stem cell transplantation, stomach cancer, superficial bladder cancer, sweat glands cancer, T-cell leukemia, T-cell lymphoma, cutaneous, testicular cancer, testis cancer, thalamu, thalamic, brain tumor, thymoma, thymus gland cancer, thyroid cancer, thyroid lymphoma, tongue cancer, tongue base cancer, transitional cell cancer of renal pelvis, transitional cell cancer of the ureter, unknown primary cancer, ureter cancer, urethra cancer, uterine cancer, uterine sarcoma, vagina cancer, vocal cord cancer, vulva cancer, Waldenstrom's macroglobulinemia, Warthin's tumor, Wilms' tumor, Zollinger-Ellis syndrome ] | ACTIVE | — |
| 009 | [ Information processing devices, namely, computer keyboards, mouse, monitors, readers, data processing equipment, compact disc players, optical character readers, computer memories, printers for use with computers, processors; computer programs and software for stockage, management, and analysis of biological information ] | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by QIAGEN MARSEILLE S.A.S.
- Other trademarks owned by QIAGEN MARSEILLE
- Other trademarks owned by QIAGEN GMBH
- Other trademarks owned by IPSOGEN
- Other trademarks owned by IPSOGEN
- Other trademarks owned by IPSOGEN
- Other trademarks in Class 005
- Other trademarks in Class 009
- Similar marks named IPSOGEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 23, 2026 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Mar 23, 2026 | RNL2 | REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Mar 23, 2026 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Mar 11, 2026 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Mar 4, 2026 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Sep 13, 2025 | PR89 | POST REGISTRATION ACTION MAILED - SEC. 8 & 9 | — |
| Sep 13, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| May 14, 2025 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Jun 7, 2024 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Sep 24, 2020 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Dec 15, 2015 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Dec 15, 2015 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Dec 15, 2015 | 9G8P | REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8 | — |
| Dec 15, 2015 | 8PRT | REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED | — |
| Dec 15, 2015 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 19, 2015 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Oct 7, 2015 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jul 14, 2011 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Jul 14, 2011 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Jul 14, 2011 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jun 2, 2011 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Jun 7, 2005 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 15, 2005 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 23, 2005 | NPUB | NOTICE OF PUBLICATION | — |
| Oct 21, 2004 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 19, 2004 | ALIE | ASSIGNED TO LIE | — |
| Oct 12, 2004 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 7, 2004 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Sep 22, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 22, 2004 | PAPER RECEIVED | — | |
| Jun 4, 2004 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 26, 2004 | 1.BD | Sec. 1(B) CLAIM DELETED | — |
| Apr 26, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 26, 2004 | PAPER RECEIVED | — | |
| Oct 23, 2003 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 13, 2003 | CFIT | CASE FILE IN TICRS | — |
| Feb 21, 2003 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Dec 13, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 13, 2002 | PAPER RECEIVED | — | |
| Jun 19, 2002 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 17, 2002 | UNPR | UNRESPONSIVE/DUPLICATE PAPER RECEIVED | — |
| Jun 14, 2002 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 15, 2002 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Mar 15, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 15, 2002 | PAPER RECEIVED | — |